![]() Hemonitor's product purports to be accurate enough to become a proper replacement for a catheter, while still costing less and being less invasive. ![]() Mayblum: "Our product will make it possible to expand the number of monitored patients and lower costs, compared with catheters." "From our understanding of the problem and a check we did at various departments in hospitals, it appears that these tests haven't really caught on." "There are a number of such companies, including Israeli ones, and these products are being used, mainly in Europe, but with rather limited success," he says. One example is technologies based on bio-impedance - the body's conductivity. Today, for example, when sepsis (an infection that causes a severe life-threatening immune reaction) is indicated, only 40% of patients are monitored in this way, and the proportion is even less for other indications."Īccording to Toume, attempts were made to replace the invasive catheter with less invasive technology, but all of them use indirect measurements they do not measure the blood flow in the main artery. ![]() This is usually done only for critical patients for whom the value of this test justifies its invasiveness, although every patient in intensive care really needs the test. Hemonitor cofounder and CTO Samer Toume explains, "Today, in order to obtain an accurate estimate of the blood flow, you have to put a catheter into the main artery. Using a smart algorithm, it is able to identify the blood flow parameters by itself." ![]() There is no need for the doctor or medical technician who looks for a special angle in a manual ultrasound. Hemonitor cofounder and CEO Tom Mayblum says, "Our device is small, and is attached as a patch below the side of the neck.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |